New Collaborations Sample Clauses

New Collaborations. Through the coordinating efforts of the Joint Management Team and with the benefit of input from subject matter experts, faculty and staff, IU and Purdue will collaborate and cooperate in good faith to identify opportunities and develop plans for new joint endeavors designed to leverage their respective strengths and capabilities in various research programs to drive workforce development, breakthrough discoveries, and the translation and commercialization of innovative solutions to societal challenges. These endeavors may include joint initiatives in, for example: (i) biomedical engineering and health sciences programs; (ii) autonomous and assisted transportation instrumentation, policy and integrity; (iii) cancer detection and therapeutics; and (iv) other types of human and animal drug discovery, among others that may be identified from time to time.
View SourceView Similar (3)
New Collaborations. This Cooperation Agreement shall not in any way ------------------ prohibit either party from collaborating or cooperating with any third party, or from undertaking projects on its own, in any area of endeavor, including but not limited to the Areas of Collaboration; provided, however, that each party shall treat the other as its -------- ------- principal collaborator as set forth in clause 2.1 and consistent therewith shall first offer the other party the opportunity to enter into any collaboration contemplated by such party in the Areas of Collaboration prior to entering into a comparable arrangement with any third party unless such party has a good faith business justification ------ for choosing not to collaborate with the other party on a particular project. In any event, the parties will use good faith efforts to inform each other prior to entering into detailed discussions with third parties about the intent to collaborate or cooperate within the Areas of Collaboration it being the intention that both parties should be free of outside constraints when evaluating the benefit of entering into a joint collaboration or cooperation. Notwithstanding anything in this Cooperation Agreement to the contrary, it is understood and agreed between the parties that nothing in this Cooperation Agreement shall prevent (i) DBI from entering into collaborations or other arrangements with third party pharmaceutical companies in connection with antimicrobial susceptibility testing associated with antimicrobial therapy or (ii) Hoechst from entering into collaborations or other arrangements with third party companies in connection with decentralized near-patient point of care testing and direct pharmaceutical therapy, provided that such third party companies are not in competition with the business of DBI as it exists as of the date hereof.
View Source

Related to New Collaborations

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.

  • Scope of Collaboration As part of the collaboration, the Controllers will act as Joint Controller. The roles of the Controller and the associated tasks are specified in more detail in Appendix 1. If one party is solely responsible for a data processing operation, this party will implement all relevant data protection provisions on its own responsibility. However, such data processing procedures are not subject to this Agreement. Joint data processing and the type of Personal Data collected and processed within the framework of collaboration are specified in Appendix 1.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).